A5008006004- Ovarian cancer diagnosis and treatment
- TGF-β signaling in diseases
- Cell Adhesion Molecules Research
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Trace Elements in Health
- Cancer Genomics and Diagnostics
- Drug Transport and Resistance Mechanisms
- Cancer-related molecular mechanisms research
- Global Cancer Incidence and Screening
- RNA modifications and cancer
- Molecular Biology Techniques and Applications
- Endometrial and Cervical Cancer Treatments
- Metal complexes synthesis and properties
- Kruppel-like factors research
- Epigenetics and DNA Methylation
- Ethics in Clinical Research
- Cancer Risks and Factors
- Endometriosis Research and Treatment
- Connective Tissue Growth Factor Research
- Cancer-related Molecular Pathways
- 14-3-3 protein interactions
- RNA Research and Splicing
- Genomics and Chromatin Dynamics
- Prenatal Screening and Diagnostics
National Cancer Institute
2011-2024
National Institutes of Health
2007-2024
Garvan Institute of Medical Research
2011-2023
St Vincent's Clinic
2012-2023
National Cancer Institute
2021
University of Calgary
2021
McMaster University
2021
The Ohio State University
2021
The University of Texas MD Anderson Cancer Center
2013-2019
Cornell University
2019
In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 deaths in the United States. Herein, American Cancer Society provides an overview occurrence based on incidence data from nationwide population-based registries mortality National Center for Health Statistics. The status early detection strategies is also reviewed. States, overall rate declined 1985 (16.6 per 100,000) to 2014 (11.8 by 29% between 1976 (10.0 2015 (6.7 33%. Ovarian encompasses a...
TGF-β has limited effects on ovarian cancer cells, but its contributions to tumor growth might be mediated through elements of the microenvironment. In present study, we tested hypothesis that TGF modulates progression by modulating contribution cancer-associated fibroblasts (CAF) are in Transcriptome profiling microdissected stromal and epithelial components high-grade serous tumors TGF-β-treated normal identified versican (VCAN) as a key upregulated target gene CAFs. Functional evaluations...
Abstract Mucinous ovarian carcinoma (MOC) is a unique subtype of cancer with an uncertain etiology, including whether it genuinely arises at the ovary or metastatic disease from other organs. In addition, molecular drivers invasive progression, high-grade and are poorly defined. We perform genetic analysis MOC across all histological grades, benign borderline mucinous tumors, compare these to tumors potential extra-ovarian sites origin. Here we show that distinct supports progressive model...
Abstract Purpose: The goal of this study was to determine the effect small changes in ATP7A expression on pharmacodynamics cisplatin, carboplatin, and oxaliplatin human ovarian carcinoma cells. Experimental Design: Drug sensitivity cellular pharmacology parameters were determined 2008 cells a subline transfected with an ATP7A-expression vector (2008/MNK). by clonogenic assay, platinum (Pt) levels measured inductively coupled plasma mass spectroscopy, copper (Cu) accumulation quantified 64Cu,...
Cells selected for resistance to cisplatin are often cross-resistant copper and vice versa, the major influx transporter transport protein 1 (CTR1) has been shown regulate uptake of cisplatin, carboplatin, oxaliplatin in yeast. To further define role hCTR1 human tumor cells, ovarian carcinoma cell line A2780 was molecularly engineered increase expression by a factor 20-fold. Enhanced A2780/hCTR1 cells associated with 6.5-fold basal steady-state content 13.7-fold initial influx, demonstrating...
The copper efflux transporters ATP7A and ATP7B sequester intracellular into the vesicular secretory pathway for export from cell. influence of these on pharmacodynamics cisplatin, carboplatin, oxaliplatin was investigated using human Menkes9 disease fibroblasts (Me32a) that do not express either transporter sublines molecularly engineered to (MeMNK) or (MeWND). Cellular levels were significantly higher in Me32a cells than MeMNK MeWND sublines. These transporter-proficient resistant cytotoxic...
Abstract Purpose: We sought to identify the subcellular compartments in which cisplatin [cis-diamminedichloroplatinum (DDP)] accumulates human ovarian carcinoma cells and define its export pathways. Experimental Design: Deconvoluting digital microscopy was used location of fluorescein-labeled DDP (F-DDP) 2008 stained with organelle-specific markers. Drugs that block vesicle movement were map traffic pattern. Results: F-DDP accumulated vesicles not detectable cytoplasm. Golgi, belonging...
In May 2016, the Division of Cancer Prevention and Control Population Sciences, National Institute, convened a workshop to discuss conceptual framework for identifying genetically testing previously diagnosed but unreferred patients with ovarian cancer other unrecognized BRCA1 or BRCA2 mutation carriers improve detection families at risk breast cancer. The concept, designated Traceback, was prompted by recognition that although mutations are frequent in women cancer, many such have not been...
Human tumor cells lines with acquired resistance to cisplatin (DDP) and carboplatin (CBDCA) are often cross-resistant copper vice versa, some DDP-resistant overexpress the export pump ATP7B. We sought demonstrate that ATP7B directly mediates DDP CBDCA by stably transfecting human carcinoma a vector designed express Increased expression of rendered all three cell tested more resistant 1-h exposure (1.6–2.6-fold), (1.5–1.6-fold), (1.2–1.4-fold). The effect on cellular pharmacology...
Some cisplatin (DDP)-resistant cells overexpress the copper export transporter ATP7B, and molecularly engineered to ATP7B are resistant DDP. The interaction of Cu with normally triggers its relocalization from perinuclear region more peripheral vesicles. To investigate DDP we examined effect on subcellular localization using human ovarian carcinoma expressing a cyan fluorescent protein (ECFP)-tagged (2008/ECFP-ATP7B). expression was confirmed in 2008/ECFP-ATP7B by Western blotting,...
Free circulating DNA (fcDNA) has many potential clinical applications, due to the non-invasive way in which it is collected. However, because of low concentration fcDNA blood, genome-wide analysis carries technical challenges that must be overcome before studies can reach their full potential. There are currently no definitive standards for collection, processing and whole-genome sequencing. We report novel detailed methodology capture high-quality methylated fcDNA, library preparation...